Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy

Table 4

Ventricular function at time of cardiotoxicity and at follow-up () in patients with only left ventricular dysfunction at the time of cardiotoxicity and in those with biventricular dysfunction.

	Cardiotoxicity	Posttreatment
Left ventricular dysfunction
EF Biplane (%)	44 ± 7	51 ± 9
GLS	−15.7 ± 2.4	−17.6 ± 3.1
FAC (%)	44 ± 5	46 ± 9
RVGLS	−22.2 ± 1.4
RVFWLS	−27.0 ± 3.2	−26.1 ± 6.6
Biventricular dysfunction based on RVGLS
EF biplane (%)	47 ± 3	52 ± 3
LV GLS	−14.4 ± 1.7	−16.4 ± 1.6
FAC	39 ± 11	48 ± 6
RVGLS	−17.8 ± 1.2	−22.3 ± 2.9
RVFWLS	−21.6 ± 2.8	−26.3 ± 5.0
Biventricular dysfunction based on RVFWLS
EF biplane (%)	49 ± 5	52 ± 2.5
LV GLS	−15.6 ± 0.8	−16.1 ± 1.1
FAC	33 ± 11	48 ± 3
RVGLS	−14.6 ± 0.7	−21.8 ± 2.1
RVFWLS	−19.5 ± 1.1	−23.5 ± 2.4

Abbreviations as per Table 2.